Stockhead TV: CEO interview on stem cell therapies entering the market

Stockhead TV's WTF series featured an in-depth interview with CEO Dr Kilian Kelly discussing the stem cell therapy industry as multiple products approach commercialisation. Host Tylah Tully explored the fundamentals of stem cell technology, its development trajectory, recent regulatory approvals, and future applications. The interview covered the history of mesenchymal stromal cell therapies, ethical considerations that have shaped the field's development, the rigorous research and clinical trial requirements for regulatory approval, and how Cynata's Cymerus™ platform advances the technology.

With MSC-based therapies now approved across multiple jurisdictions including the US, EU, Japan, Korea and Australia, and Japan's recent conditional approval of the first iPSC-derived regenerative medicines in early 2026, the discussion provided timely context on the maturation of the cell therapy sector and Cynata's position within it.

Watch the interview: https://tinyurl.com/48t5j9ex